Administration of bovine polymerized haemoglobin before and during coronary occlusion reduces infarct size in rabbits.
Standard
Administration of bovine polymerized haemoglobin before and during coronary occlusion reduces infarct size in rabbits. / Rempf, Christian; Standl, T; Schenke, K; Chammas, K; Gottschalk, A; Burmeister, M-A.
in: BRIT J ANAESTH, Jahrgang 103, Nr. 4, 4, 2009, S. 496-504.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Administration of bovine polymerized haemoglobin before and during coronary occlusion reduces infarct size in rabbits.
AU - Rempf, Christian
AU - Standl, T
AU - Schenke, K
AU - Chammas, K
AU - Gottschalk, A
AU - Burmeister, M-A
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Haemoglobin-based oxygen carriers (HBOC) seem to increase the risk of mortality and myocardial infarction in clinical trials. Therefore, we designed this randomized placebo-controlled animal study to evaluate the effects of prophylactic and therapeutic administration of HBOC in a myocardial ischaemia-reperfusion model with respect to infarct size and areas of impaired perfusion (no reflow, NR). METHODS: Thirty-two anaesthetized, mechanically ventilated rabbits were randomized to one of the four groups. Group G1 received 0.4 g kg(-1) i.v. HBOC-200 25 min before coronary artery occlusion, G2 received the same dose i.v. 10 min after occlusion, and G3 and 4 received i.v. saline. G1, 2, and 3 were subjected to 30 min occlusion of left coronary artery followed by 240 min of reperfusion. G4 was treated without ischaemia-reperfusion. Measurement included assessment of the area at risk and infarct size using triphenyltetrazolium chloride stain and areas of NR using thioflavin stain. Ischaemia-reperfusion was confirmed by microspheres technique. RESULTS: Infarct size as a percentage of the area at risk was significantly reduced in G1 [25 (sd 13)%, P=0.026] and G2 [22 (20)%, P=0.009] compared with G3 [48 (17)%]. The areas of NR in percentage of the area at risk [G1, 26 (15)%; G2, 34 (22)%; G3, 36 (12)%; G4, 5 (3)%] did not differ between the groups of animals undergoing coronary occlusion and reperfusion. CONCLUSIONS: Prophylactic and therapeutic administration of HBOC-200 reduces infarct size in myocardial ischaemia and reperfusion in rabbits. This reduction of infarct size is not accompanied by an improvement of areas of NR.
AB - BACKGROUND: Haemoglobin-based oxygen carriers (HBOC) seem to increase the risk of mortality and myocardial infarction in clinical trials. Therefore, we designed this randomized placebo-controlled animal study to evaluate the effects of prophylactic and therapeutic administration of HBOC in a myocardial ischaemia-reperfusion model with respect to infarct size and areas of impaired perfusion (no reflow, NR). METHODS: Thirty-two anaesthetized, mechanically ventilated rabbits were randomized to one of the four groups. Group G1 received 0.4 g kg(-1) i.v. HBOC-200 25 min before coronary artery occlusion, G2 received the same dose i.v. 10 min after occlusion, and G3 and 4 received i.v. saline. G1, 2, and 3 were subjected to 30 min occlusion of left coronary artery followed by 240 min of reperfusion. G4 was treated without ischaemia-reperfusion. Measurement included assessment of the area at risk and infarct size using triphenyltetrazolium chloride stain and areas of NR using thioflavin stain. Ischaemia-reperfusion was confirmed by microspheres technique. RESULTS: Infarct size as a percentage of the area at risk was significantly reduced in G1 [25 (sd 13)%, P=0.026] and G2 [22 (20)%, P=0.009] compared with G3 [48 (17)%]. The areas of NR in percentage of the area at risk [G1, 26 (15)%; G2, 34 (22)%; G3, 36 (12)%; G4, 5 (3)%] did not differ between the groups of animals undergoing coronary occlusion and reperfusion. CONCLUSIONS: Prophylactic and therapeutic administration of HBOC-200 reduces infarct size in myocardial ischaemia and reperfusion in rabbits. This reduction of infarct size is not accompanied by an improvement of areas of NR.
KW - Animals
KW - Male
KW - Disease Models, Animal
KW - Blood Pressure drug effects
KW - Blood Substitutes therapeutic use
KW - Carbon Dioxide blood
KW - Cattle
KW - Coronary Circulation drug effects
KW - Drug Evaluation, Preclinical methods
KW - Heart Rate drug effects
KW - Hemoglobins therapeutic use
KW - Myocardial Infarction pathology
KW - Myocardial Reperfusion Injury pathology
KW - Oxygen blood
KW - Partial Pressure
KW - Rabbits
KW - Animals
KW - Male
KW - Disease Models, Animal
KW - Blood Pressure drug effects
KW - Blood Substitutes therapeutic use
KW - Carbon Dioxide blood
KW - Cattle
KW - Coronary Circulation drug effects
KW - Drug Evaluation, Preclinical methods
KW - Heart Rate drug effects
KW - Hemoglobins therapeutic use
KW - Myocardial Infarction pathology
KW - Myocardial Reperfusion Injury pathology
KW - Oxygen blood
KW - Partial Pressure
KW - Rabbits
M3 - SCORING: Zeitschriftenaufsatz
VL - 103
SP - 496
EP - 504
JO - BRIT J ANAESTH
JF - BRIT J ANAESTH
SN - 0007-0912
IS - 4
M1 - 4
ER -
